Since then, PODXL has been found to be overexpressed in numerous cancer types and associated with a more aggressive tumour phenotype and poor outcome in breast [5], prostate [6], colorectal [7,8] ovarian [9] and bladder cancer [10]. Here, PODXL is linked to cancer.